Furthermore, a reduction of [123I]FP-CIT SPECT greater than 25% in the putamen has been shown to discriminate iRBD patients, with DAT deficits, who converted to a synucleinopathy from iRBD patients who did not convert after three-year follow-up [43]. Here, SLC6A3 is linked to synucleinopathy.